Red Light Holland's Radix Motion 3D Movement Data and AI Innovations Patent Application Granted Entry to "Patent Prosecution Highway" (PPH) and Accorded "Special" Status
Toronto, Ontario--(Newsfile Corp. - June 1, 2023) - Radix Motion, a fully-owned technology subsidiary of Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws, is pleased to announce that further to its press release dated January 31, 2023, its U.S. "continuation-in-part" (CIP) application has been granted the right to participate in the "Patent Prosecution Highway" program and accorded "special" status.
The Patent Prosecution Highway (PPH) is a fast-track examination procedure that allows applicants to reach final disposition of a patent application more quickly and efficiently than standard examination processing. As applications examined under the PPH program have a higher likelihood of allowance, it is hoped this decision will swiftly lead to an issued patent in the U.S., and subsequently in other PPH jurisdictions where a PPH request is also granted.
Radix Motion's claims are directed to the use of human movement data in psychedelic-assisted therapy, including as a tool to promote positive experiences, to prevent negative experiences, to predict and personalize individual patient experiences, and to evaluate the efficacy of the therapy.
The patent application also covers Radix Motion's technology on the use of real-time analysis of human movement data to identify the position and body movement of a psychedelic facilitator or therapist to detect if a potential violation is occurring and activate real time alerts and safety measures. This technology does not require sending or storing any video information and helps to protect patient privacy.
With this new technology, Radix Motion is leading the way in creating safer and more private psychedelic therapy sessions for clients.
"There is a huge opportunity to improve trust, safety and privacy both for clients and facilitators in psychedelic sessions with this technology which we believe will ultimately lead to better efficacy," said Sarah Hashkes, CEO of Radix Motion and CTIO or Red Light Holland. "Human movement data in combination with AI is also an untapped gold mine for clinical research and new psychedelic compound development."
"Getting accepted into the Patent Prosecution Highway program is a great boost toward receiving a timely and cost effective patent," said Graham Pechenik, a registered patent attorney and the founder of Calyx Law, and Red Light Holland's senior advisor. "We appreciate the opportunity to protect Radix Motion's inventions, in ways that are aligned with its goal of ethical IP and its core value of protecting user's privacy".
"We're proud that our embodied technology can help establish responsible best practices around psychedelics and contribute to positive change in the emerging psychedelic ecosystem. This patent application is an important milestone for us, and we believe that the potential licensing or sale of this technology could provide another revenue stream for Red Light Holland. We appreciate the expertise of patent lawyer Graham Pechenik and the Calyx Law team in protecting our investment, particularly under the Patent Prosecution Highway program," said Todd Shapiro, CEO and Director of Red Light Holland.
About Radix Motion
Radix Motion is a technology company founded in Silicon Valley focused on building immersive and embodied technology for health and wellness. Amongst their products are Meu, an AR/VR interactive hologram messenger, iMicroapp a microdosing app that also measures poses, Wisdom VR, an interactive education that explains what psychedelics do to the brain and more.
About Red Light Holland
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.
For additional information, please contact:
Todd Shapiro
Chief Executive Officer and Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co
Forward-Looking Information and Cautionary Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events.
The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company's performance, business objectives and milestones and the anticipated timing of, and costs in connection with, the execution or achievement of such objectives and milestones; the Company's intention to devote resources to the protection of its intellectual property rights, including the use of the PPH procedure; the Company and Radix Motion's continued eligibility to participate in the fast-track examination offered by the Patent Prosecution Highway in the U.S., Canada, and other participating patent offices; the potential benefits of the PPH program, including the improvement of trust, safety, and privacy for clients and facilitators, the likelihood of allowance, cost effectiveness and expediency of the PPH program, and the PPH's alignment with Radix Motion's goal of ethical IP and its core value of protecting user's privacy; the potential benefits of psychedelic usage data, including clinical research and psychedelic compound development; Radix Motion's technology will help it lead the way by being an invaluable asset in creating safer and more private psychedelic therapy sessions for clients; the Company's technology can help establish responsible best practices around psychedelics and contribute to positive change in the emerging psychedelic ecosystem; the patent application being an important milestone for the Company, and its belief that the potential licensing or sale of its technology could provide another revenue stream the Company.
Forward-looking information in this press release are based on certain assumptions and expected future events, namely: the Company's ability to maintain or achieve its performance, business objectives and milestones and the anticipated timing of, and costs in connection with, the execution or achievement of such objectives and milestones; the Company's ability to devote resources to the protection of its intellectual property rights, including the use of the PPH procedure; the Company and Radix Motion's ability to maintain their continued eligibility to participate in the fast-track examination offered by the Patent Prosecution Highway in the U.S., Canada, and other participating patent offices; the continued availability and the Company's realisation of the potential benefits of the PPH program, including the the improvement of trust, safety, and privacy for clients and facilitators, the likelihood of allowance, cost effectiveness and expediency of the PPH program, and the PPH's alignment with Radix Motion's goal of ethical IP and its core value of protecting user's privacy; the Company's realisation of the potential benefits of psychedelic usage data, including clinical research and psychedelic compound development; Radix Motion's ability to realise on its technology will help it lead the way by being an invaluable asset in creating safer and more private psychedelic therapy sessions for clients; the Company ability to use its technology to help establish responsible best practices around psychedelics and contribute to positive change in the emerging psychedelic ecosystem; the patent application will be an important milestone for the Company; and that the potential licensing or sale of its technology will provide another revenue stream the Company.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to:the Company's inability to maintain or achieve its performance, business objectives and milestones and the anticipated timing of, and costs in connection with, the execution or achievement of such objectives and milestones; the Company's inability to devote resources to the protection of its intellectual property rights, including the use of the PPH procedure; the Company and Radix Motion's inability to maintain their continued eligibility to participate in the fast-track examination offered by the Patent Prosecution Highway in the U.S., Canada, and other participating patent offices; the lack of availability and the Company's inability to realise the potential benefits of the PPH program, including the the improvement of trust, safety, and privacy for clients and facilitators, the likelihood of allowance, cost effectiveness and expediency of the PPH program, and the PPH's alignment with Radix Motion's goal of ethical IP and its core value of protecting user's privacy; the Company's inability to realise the potential benefits of psychedelic usage data, including clinical research and psychedelic compound development; Radix Motion's inability to realise on its technology will help it lead the way by being an invaluable asset in creating safer and more private psychedelic therapy sessions for clients; the Company's inability to use its technology to help establish responsible best practices around psychedelics and contribute to positive change in the emerging psychedelic ecosystem; the patent application will not be an important milestone for the Company; and that the potential licensing or sale of its technology will not provide another revenue stream the Company.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/168340
